HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jaime Acquaviva Selected Research

STA 9090

12/2018Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
6/2015The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
2/2014Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
2/2014Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
1/2014Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
4/2013Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
1/2013Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
12/2012Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jaime Acquaviva Research Topics

Disease

15Neoplasms (Cancer)
12/2018 - 11/2008
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2015 - 12/2012
2Carcinogenesis
10/2010 - 11/2008
1Urinary Bladder Neoplasms (Bladder Cancer)
07/2014
1Breast Neoplasms (Breast Cancer)
02/2014
1Inflammatory Breast Neoplasms
02/2014
1Melanoma (Melanoma, Malignant)
02/2014
1Neoplasm Metastasis (Metastasis)
01/2014
1Triple Negative Breast Neoplasms
01/2014
1Prostatic Neoplasms (Prostate Cancer)
01/2013
1Lung Neoplasms (Lung Cancer)
12/2012
1Glioblastoma (Glioblastoma Multiforme)
12/2011
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
10/2010
1Lymphoma (Lymphomas)
10/2010
1Genetic Translocation (Chromosomal Translocation)
10/2010
1Multiple Myeloma
10/2010
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
10/2010

Drug/Important Bio-Agent (IBA)

8STA 9090IBA
12/2018 - 12/2012
5Molecular Chaperones (Chaperone, Molecular)IBA
07/2014 - 12/2012
3Heat-Shock Proteins (Heat-Shock Protein)IBA
12/2018 - 01/2013
3ErbB Receptors (EGF Receptor)IBA
06/2015 - 02/2009
2Pharmaceutical PreparationsIBA
11/2015 - 07/2014
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2014 - 02/2014
2Proteins (Proteins, Gene)FDA Link
02/2014 - 01/2013
1Biological ProductsIBA
12/2018
1ProdrugsIBA
12/2018
1STA-1474IBA
12/2018
1STA-12-8666IBA
11/2015
1Topoisomerase I InhibitorsIBA
11/2015
1Irinotecan (Camptosar)FDA LinkGeneric
11/2015
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2015
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2015
1Gefitinib (Iressa)FDA Link
06/2015
1Oncogene Proteins (Oncogene Protein)IBA
05/2014
1Lapatinib (GW572016)FDA Link
02/2014
1TAK 733IBA
02/2014
1Hormones (Hormone)IBA
02/2014
1Proto-Oncogene Proteins B-rafIBA
02/2014
1Transcription Factors (Transcription Factor)IBA
02/2014
1tyrosine receptor (receptor, tyrosine)IBA
02/2014
1VemurafenibIBA
02/2014
1Anaplastic Lymphoma KinaseIBA
04/2013
1CrizotinibIBA
04/2013
1Phosphotransferases (Kinase)IBA
04/2013
1AndrogensIBA
01/2013
1Androgen Receptors (Androgen Receptor)IBA
01/2013
1LigandsIBA
12/2011
1Interferon Regulatory FactorsIBA
10/2010
1interferon regulatory factor-8 (interferon consensus sequence binding protein)IBA
10/2010
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2009

Therapy/Procedure

6Therapeutics
06/2015 - 11/2008
1Drug Therapy (Chemotherapy)
01/2014